
Birol Emir

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11934410/publications.pdf Version: 2024-02-01



RIDOL FMID

#	Article	IF	CITATIONS
1	Pandemic-related declines in hospitalization for non-COVID-19-related illness in the United States from January through July 2020. PLoS ONE, 2022, 17, e0262347.	2.5	21
2	Real-World Treatment Patterns and Clinical Effectiveness of Palbociclib Plus an Aromatase Inhibitor as First-Line Therapy in Advanced/Metastatic Breast Cancer: Analysis from the US Syapse Learning Health Network. Current Oncology, 2022, 29, 1047-1061.	2.2	4
3	Increasing access to erectile dysfunction treatment via pharmacies to improve healthcare provider visits and quality of life: Results from a prospective realâ€world observational study in the United Kingdom. International Journal of Clinical Practice, 2021, 75, e13849.	1.7	6
4	Comparative effectiveness of first-line palbociclib plus letrozole versus letrozole alone for HR+/HER2â^' metastatic breast cancer in US real-world clinical practice. Breast Cancer Research, 2021, 23, 37.	5.0	65
5	Finite Mixture Models, a Flexible Alternative to Standard Modeling Techniques for Extrapolated Mean Survival Times Needed for Cost-Effectiveness Analyses. Value in Health, 2021, 24, 1643-1650.	0.3	2
6	Effectiveness and Safety of Apixaban Versus Warfarin Among Older Patients with Venous Thromboembolism with Different Demographics and Socioeconomic Status. Advances in Therapy, 2021, 38, 5519-5533.	2.9	7
7	Effectiveness and Safety of Apixaban vs. Warfarin in Venous Thromboembolism Patients with Obesity and Morbid Obesity. Journal of Clinical Medicine, 2021, 10, 200.	2.4	21
8	Treatment patterns and survival in metastatic castrationâ€sensitive prostate cancer in the US Veterans Health Administration. Cancer Medicine, 2021, 10, 8570-8580.	2.8	22
9	Anticoagulation Treatment and Outcomes of Venous Thromboembolism by Weight and Body Mass Index: Insights From the Veterans Health Administration. Circulation: Cardiovascular Quality and Outcomes, 2021, 14, e008005.	2.2	10
10	Assessing the Value of Time Series Real-World and Clinical Trial Data vs. Baseline-Only Data in Predicting Responses to Pregabalin Therapy for Patients with Painful Diabetic Peripheral Neuropathy. Clinical Drug Investigation, 2019, 39, 775-786.	2.2	3
11	<p>Integrating Machine Learning With Microsimulation to Classify Hypothetical, Novel Patients for Predicting Pregabalin Treatment Response Based on Observational and Randomized Data in Patients With Painful Diabetic Peripheral Neuropathy</p> . Journal of Pragmatic and Observational Research, 2019, Volume 10, 67-76.	1.5	5
12	Dose Titration of Pregabalin in Patients with Painful Diabetic Peripheral Neuropathy:ÂSimulation Based on Observational Study Patients Enriched with Data from Randomized Studies. Advances in Therapy, 2018, 35, 382-394.	2.9	6
13	Using time series analysis approaches for improved prediction of pain outcomes in subgroups of patients with painful diabetic peripheral neuropathy. PLoS ONE, 2018, 13, e0207120.	2.5	10
14	Predictive Modeling of Response to Pregabalin for the Treatment of Neuropathic Pain Using 6-Week Observational Data: A Spectrum of Modern Analytics Applications. Clinical Therapeutics, 2017, 39, 98-106.	2.5	9
15	Integrating data from randomized controlled trials and observational studies to predict the response to pregabalin in patients with painful diabetic peripheral neuropathy. BMC Medical Research Methodology, 2017, 17, 113.	3.1	6
16	Improvement in pain severity category in clinical trials of pregabalin. Journal of Pain Research, 2016, Volume 9, 779-785.	2.0	10
17	Pain relief and functional improvement in patients with neuropathic pain associated with spinal cord injury: an exploratory analysis of pregabalin clinical trials. Journal of Pain Research, 2016, 9, 405.	2.0	9
18	Prior Opioid Use Does Not Impact the Response to Pregabalin in Patients With Fibromyalgia. Clinical Journal of Pain, 2016, 32, 555-561.	1.9	5

BIROL EMIR

#	Article	IF	CITATIONS
19	Examining the Time to Improvement of Sleep Interference With Pregabalin in Patients With Painful Diabetic Peripheral Neuropathy and Postherpetic Neuralgia. American Journal of Therapeutics, 2015, 22, 257-268.	0.9	17
20	Electronic medical record data to identify variables associated with a fibromyalgia diagnosis: importance of health care resource utilization. Journal of Pain Research, 2015, 8, 131.	2.0	12
21	Predictors of placebo response in peripheral neuropathic pain: insights from pregabalin clinical trials. Journal of Pain Research, 2015, 8, 257.	2.0	22
22	Temporal analysis of pain responders and common adverse events: when do these first appear following treatment with pregabalin. Journal of Pain Research, 2015, 8, 303.	2.0	13
23	Time to Improvement of Pain and Sleep Quality in Clinical Trials of Pregabalin for the Treatment of Fibromyalgia. Pain Medicine, 2015, 16, 176-185.	1.9	17
24	Examining the Time to Therapeutic Effect of Pregabalin in Spinal Cord Injury Patients With Neuropathic Pain. Clinical Therapeutics, 2015, 37, 1081-1090.	2.5	13
25	A Comprehensive Drug Safety Evaluation of Pregabalin in Peripheral Neuropathic Pain. Pain Practice, 2015, 15, 47-57.	1.9	61
26	Efficacy and safety of pregabalin in generalised anxiety disorder: A critical review of the literature. Journal of Psychopharmacology, 2015, 29, 1047-1060.	4.0	47
27	Identification of a potential fibromyalgia diagnosis using random forest modeling applied to electronic medical records. Journal of Pain Research, 2015, 8, 277-88.	2.0	9
28	Prediction of Pregabalin-Mediated Pain Response by Severity of Sleep Disturbance in Patients with Painful Diabetic Neuropathy and Post-Herpetic Neuralgia. Pain Medicine, 2014, 15, 661-670.	1.9	45
29	Sensory profiles of patients with neuropathic pain based on the neuropathic pain symptoms and signs. Pain, 2014, 155, 367-376.	4.2	176
30	Relationship Between Pain Relief and Improvements in Patient Function/Quality of Life in Patients With Painful Diabetic Peripheral Neuropathy or Postherpetic Neuralgia Treated With Pregabalin. Clinical Therapeutics, 2013, 35, 612-623.	2.5	65
31	Efficacy and safety of pregabalin in patients with spinal cord injury: a pooled analysis. Current Medical Research and Opinion, 2013, 29, 1675-1683.	1.9	18
32	Long-term treatment of anxiety disorders with pregabalin: a 1 year open-label study of safety and tolerability. Current Medical Research and Opinion, 2013, 29, 1223-1230.	1.9	28
33	Characterizing and understanding body weight patterns in patients treated with pregabalin. Current Medical Research and Opinion, 2012, 28, 1027-1037.	1.9	31
34	Development of responder definitions for fibromyalgia clinical trials. Arthritis and Rheumatism, 2012, 64, 885-894.	6.7	42
35	Correlations between Fibromyalgia Symptom and Function Domains and Patient Global Impression of Change: A Pooled Analysis of Three Randomized, Placebo-Controlled Trials of Pregabalin. Pain Medicine, 2011, 12, 260-267.	1.9	22
36	Time to Onset of Neuropathic Pain Reduction: A Retrospective Analysis of Data From Nine Controlled Trials of Pregabalin for Painful Diabetic Peripheral Neuropathy and Postherpetic Neuralgia. American Journal of Therapeutics, 2010, 17, 577-585.	0.9	49

BIROL EMIR

#	Article	IF	CITATIONS
37	Evaluation of the safety and efficacy of pregabalin in older patients with neuropathic pain: results from a pooled analysis of 11 clinical studies. BMC Family Practice, 2010, 11, 85.	2.9	71
38	Treatment response to pregabalin in fibromyalgia pain: effect of patient baseline characteristics. Expert Opinion on Pharmacotherapy, 2010, 11, 2275-2280.	1.8	5
39	Pregabalin in Treatment-Refractory Fibromyalgia. Open Rheumatology Journal, 2010, 4, 35-38.	0.2	7
40	Pregabalin in the Treatment of Refractory Neuropathic Pain: Results of a 15-Month Open-Label Trial. Pain Medicine, 2008, 9, 1202-1208.	1.9	56
41	Efficacy, Safety, and Tolerability of Pregabalin Treatment for Painful Diabetic Peripheral Neuropathy. Diabetes Care, 2008, 31, 1448-1454.	8.6	280
42	Efficacy of Donepezil on Maintenance of Activities of Daily Living in Patients with Moderate to Severe Alzheimer's Disease and the Effect on Caregiver Burden. Journal of the American Geriatrics Society, 2003, 51, 737-744.	2.6	189
43	Efficacy of Donepezil on Behavioral Symptoms in Patients With Moderate to Severe Alzheimer's Disease. International Psychogeriatrics, 2002, 14, 389-404.	1.0	211
44	Comparison of diagnostic markers with repeated measurements: a non-parametric ROC curve approach. , 2000, 19, 511-523.		19
45	Analysis of repeated markers used to predict progression of cancer. , 1998, 17, 2563-2578.		38